Optimizing the detection of methicillin-resistant Staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range

References

• MoelleringRCVancomycin: a 50-year reassessmentClin Infect Dis200642Supp1S3S416323117
   PubMed Web of Science ®Google Scholar
• RubinsteinEKeynanYVancomycin revisited – 60 years laterFront Public Health2014221725401098
   PubMedGoogle Scholar
• DeresinskiSVancomycin and Staphylococcus aureus – an antibiotic enters obsolescenceClin Infect Dis200744121543154817516396
   PubMed Web of Science ®Google Scholar
• DeresinskiSVancomycin: does it still have a role as an antistaphylococcal agent?Expert Rev Anti Infect Ther20075339340117547504
   PubMed Web of Science ®Google Scholar
• YuTStockmannCBalchAHSpigarelliMGSherwinCMEvolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999–2012Int J Antimicrob Agents201443321522224183801
   PubMed Web of Science ®Google Scholar
• PerezFSalataRABonomoRACurrent and novel antibiotics against resistant Gram-positive bacteriaInfect Drug Resist20081274421694878
   PubMedGoogle Scholar
• KollefMHLimitations of vancomycin in the management of resistant staphylococcal infectionsClin Infect Dis200745Suppl 3S191S19517712746
   PubMed Web of Science ®Google Scholar
• DhandASakoulasGReduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (‘the MIC Creep’): implications for therapyF1000 Med Rep20124422312414
   PubMedGoogle Scholar
• Moise-BroderPAForrestABirminghamMCSchentagJJPharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infectionsClin Pharmacokinet2004431392594215509186
   PubMed Web of Science ®Google Scholar
• LodiseTPDrusanoGLZasowskiEVancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?Clin Infect Dis201459566667524867791
   PubMed Web of Science ®Google Scholar
• RybakMJLomaestroBMRotschaferJCVancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases PharmacistsClin Infect Dis200949332532719569969
   PubMed Web of Science ®Google Scholar
• TenoverFCMoelleringRCJrThe rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureusClin Infect Dis20074491208121517407040
   PubMed Web of Science ®Google Scholar
• HollandTLFowlerVGJrVancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet?J Infect Dis2011204332933121742827
   PubMed Web of Science ®Google Scholar
• JacobJTDiazGranadosCAHigh vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysisInt J Infect Dis2013172e93e10023089040
   PubMed Web of Science ®Google Scholar
• HsuDIHidayatLKQuistRComparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infectionsInt J Antimicrob Agents200832537838518701261
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards InstituteMethods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard: Ninth Edition M07-A9Wayne, PACLSI2012
   Google Scholar
• TongSYBishopEJLilliebridgeRACommunity-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in indigenous Northern Australia: epidemiology and outcomesJ Infect Dis2009199101461147019392622
   PubMed Web of Science ®Google Scholar
• NimmoGRCoombsGWPearsonJCMethicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemicMed J Aust2006184838438816618236
   PubMed Web of Science ®Google Scholar
• WiYMKimJMJooEJHigh vancomycin minimum inhibitory concentration is a predictor of mortality in methicillin-resistant Staphylococcus aureus bacteraemiaInt J Antimicrob Agents201240210811322633565
   PubMed Web of Science ®Google Scholar
• van HalSJBarbagiannakosTJonesMMethicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patternsJ Antimicrob Chemother201166102284228721750101
   PubMed Web of Science ®Google Scholar
• KhatibRRiedererKShemesSMustaACSzpunarSCorrelation of methicillin-resistant Staphylococcus aureus vancomycin minimal inhibitory concentration results by Etest and broth microdilution methods with population analysis profile: lack of Etest overestimation of the MICEur J Clin Microbiol Infect Dis201332680380623307411
   PubMed Web of Science ®Google Scholar
• KeelRASutherlandCAAslanzadehJNicolauDPKutiJLCorrelation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologiesDiag Microbiol Infect Dis2010683326329
   Web of Science ®Google Scholar
• MasonEOLamberthLBHammermanWAHultenKGVersalovicJKaplanSLVancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005J Clin Microbiol20094761628163019403769
   PubMed Web of Science ®Google Scholar
• Van HalSJLodiseTPPatersonDLThe clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysisClin Infect Dis201254675577122302374
   PubMed Web of Science ®Google Scholar
• LiuCBayerACosgroveSEClinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summaryClin Infect Dis201152328529221217178
   PubMed Web of Science ®Google Scholar